IRIS
LARONI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 10.979
AS - Asia 575
SA - Sud America 73
NA - Nord America 61
AF - Africa 9
Totale 11.697
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 10.965
SG - Singapore 251
CN - Cina 150
VN - Vietnam 122
BR - Brasile 46
US - Stati Uniti d'America 40
HK - Hong Kong 19
MX - Messico 19
AR - Argentina 15
ID - Indonesia 8
EC - Ecuador 4
IQ - Iraq 4
PK - Pakistan 4
BD - Bangladesh 3
PY - Paraguay 3
GB - Regno Unito 2
HR - Croazia 2
JO - Giordania 2
NL - Olanda 2
OM - Oman 2
RU - Federazione Russa 2
ZA - Sudafrica 2
AO - Angola 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CO - Colombia 1
CV - Capo Verde 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
ES - Italia 1
GF - Guiana Francese 1
HT - Haiti 1
HU - Ungheria 1
IE - Irlanda 1
IL - Israele 1
IR - Iran 1
JP - Giappone 1
KE - Kenya 1
KZ - Kazakistan 1
LB - Libano 1
LT - Lituania 1
MM - Myanmar 1
PE - Perù 1
PH - Filippine 1
RO - Romania 1
SA - Arabia Saudita 1
SO - Somalia 1
TN - Tunisia 1
VE - Venezuela 1
Totale 11.697
Salva come PNG Salva come JPEG
Città #
Genova 5.668
Genoa 3.507
Vado Ligure 967
Rapallo 781
Singapore 81
Beijing 47
Ho Chi Minh City 47
Hanoi 27
Ashburn 23
Bordighera 20
Hong Kong 19
Mexico City 15
Haiphong 8
Rome 6
Tianjin 6
Biên Hòa 5
New York 5
Da Nang 3
Guangzhou 3
Karachi 3
Los Angeles 3
Quảng Ngãi 3
Sorocaba 3
São Paulo 3
Thái Bình 3
Vũng Tàu 3
Amman 2
Asunción 2
Bari 2
Changsha 2
Contagem 2
Curitiba 2
Hangzhou 2
Jakarta 2
Johannesburg 2
Ninh Bình 2
Porto Alegre 2
Rio de Janeiro 2
Thái Nguyên 2
Vĩnh Tường 2
Zagreb 2
Almaty 1
Amsterdam 1
Arad 1
Arequipa 1
Aryanah 1
Baghdad 1
Baku 1
Banyuwangi 1
Beirut 1
Belém 1
Blumenau 1
Bologna 1
Bonao 1
Budapest 1
Buon Ma Thuot 1
Bình Dương 1
Cairo 1
Can Tho 1
Cao Lanh 1
Caracas 1
Cariacica 1
Catamarca 1
Cayenne 1
Chongqing 1
Ciudad del Este 1
Concordia 1
Coronel Freitas 1
Coronel Vidal 1
Coronel Vivida 1
Cotia 1
Cuautitlán Izcalli 1
Cuenca 1
Dallas 1
Delmas 1
Dublin 1
Duque de Caxias 1
El Pueblito 1
Erbil 1
Flores da Cunha 1
Frutal 1
General Trias 1
Gramado 1
Guarapuava 1
Guayaquil 1
Ha Long 1
Hamad Town 1
Hargeisa 1
Hillah 1
Iguape 1
Indaiatuba 1
Itajubá 1
Itanhaém 1
Jardín América 1
Jequié 1
Jinan 1
Juazeiro do Norte 1
Karbala 1
La Paz 1
Lahore 1
Totale 11.348
Salva come PNG Salva come JPEG
Nome #
Composite MRI measures and short-term disability in patients with clinically isolated syndrome suggestive of MS 241
Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy 227
Finger motor performance as a new quantitative clinical endpoint in multiple sclerosis 220
Neuroprotective features of mesenchymal stem cells. 201
Association of melanoma and natalizumab therapy in the Italian MS population: a second case report. 200
Early switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruption 194
Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. 178
In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma 174
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis 173
Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. 172
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 165
Three years of experience: the Italian registry and safety data update 159
Activation of the aryl hydrocarbon receptor induces human type 1 regulatory T cell-like and Foxp3(+) regulatory T cells. 155
A case of thyroiditis during natalizumab therapy for multiple sclerosis 151
Cardiovascular autonomic individual profile of relapsing-remitting multiple sclerosis patients and risk of extending cardiac monitoring after first dose fingolimod 151
T-cell trafficking in the central nervous system. 150
A multicentRE observational analysiS of PErsistenCe to Treatment in the new multiple sclerosis era: the RESPECT study 150
Teriflunomide treatment reduces B cells in patients with MS. 148
Hypothalamic AgRP neurons control hematopoiesis and lymphopoiesis and are activated in experimental MS 147
Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis 146
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. 145
Approved drugs for multiple sclerosis: The challenge of choice 144
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study 143
Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial. 142
Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases 140
Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation 134
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 133
Serum sickness (Like Reaction) in a patient treated with alemtuzumab for multiple sclerosis: A case report 132
Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity 131
Role of the innate immune system in the pathogenesis of multiple sclerosis. 130
Can we kill an extra bird with the same stone? 128
JCV-DNA testing during natalizumab treatment is complementary to anti-JCV antibodies for PML risk stratification 127
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis 127
Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome 125
Wernicke's syndrome during parenteral feeding: not an unusual complication. 124
Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma? 124
Early diagnosis of progressive multifocal leucoencephalopathy: longitudinal lesion evolution 123
Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group 123
Mesenchymal stem cells as treatment for MS - progress to date. 122
Regulatory Functions of Natural Killer Cells in Multiple Sclerosis 121
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. 120
IL-27 imparts immunoregulatory function to human NK cell subsets. 118
To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy 113
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 112
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 111
Dysregulation of regulatory CD56 (bright) NK cells/T cells interactions in multiple sclerosis 110
Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab 110
Impact of treatment on cellular immunophenotype in MS: A cross-sectional study 106
MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis 105
Clinical, laboratory features, and prognostic factors in adult acute transverse myelitis: an Italian multicenter study 105
Assessing upper limb function in Multiple Sclerosis by an engineered glove 105
The early effect of cladribrine versus fingolimod on clinical and MRI measures in relapsing remitting multiple sclerosis 101
Epstein-Barr-negative MS: a true phenomenon? 101
Long-term disability progression in primary progressive multiple sclerosis: A 15-year study 101
Natural killer cells are functionally defective in multiple sclerosis 100
The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL 100
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks 100
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks 99
Multiple sclerosis and autoimmune diseases: epidemiology and HLA-DR association in North-east Italy. 99
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy 99
Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system. 98
The short-chain fatty acid butyrate decreases the regulatory function of human natural killer cells and promotes their maturation 97
Factors interfering with parenthood decision-making in an Italian sample of people with multiple sclerosis: an exploratory online survey 96
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 95
A pilot study comparing myelin measurements from [18F]-Florbetaben PET and quantitative T1 map imaging in multiple sclerosis (MS) 94
Enhancing natural killer cells is beneficial in multiple sclerosis - Yes 93
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study 93
Impact of Natural Killer (NK) Cells on Immune Reconstitution, and Their Potential as a Biomarker of Disease Activity, in Alemtuzumab-Treated Patients with Relapsing Remitting Multiple Sclerosis: An Observational Study 93
Impaired suppressor function of NK cells in multiple sclerosis 92
Interferon beta potentiates the therapeutic activity of mesenchymal stem cells 87
Health-related quality of life in multiple sclerosis: Effects of natalizumab 86
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 84
Impaired suppressor function of CD56bright NK cells in early multiple sclerosis 82
Aging with multiple sclerosis: Clinical characterization of an elderly population, a cross-sectional study 81
CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis 79
Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis 77
Multivariate clinically isolated syndrome (CIS) risk factor study: towards individual prognosis and treatment indication in CIS 76
COVID-19 in patients with multiple sclerosis undergoing disease-modifying treatments 76
Beyond steady-state amyloid PET to detect demyelination in multiple sclerosis (MS) 75
Mesenchymal stem cells for the treatment of neurological diseases: Immunoregulation beyond neuroprotection 74
MESEMS: a randomized, double blind placebo-controlled cross-over study to evaluate safety and efficacy of intravenous administration of autologous mesenchymal stem cells in patients with multiple sclerosis 72
CD56bright Natural Killer Cells: A Possible Biomarker of Different Treatments in Multiple Sclerosis 72
Tailoring B cell depletion therapy in MS according to memory B cell monitoring 72
A real-world study of alemtuzumab in a cohort of Italian patients 71
The effect of Cladribine and Fingolimod treatments on retinal atrophy 69
Effect of ocrelizumab treatment on retinal atrophy: preliminary results from a single-center observational study 69
Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic? 69
Mesenchymal stem cells for multiple sclerosis: effect of treatment on peripheral immune cells 68
Nonfunctional natural killer regulatory cells in multiple sclerosis 68
Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: who gains from it? 67
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 67
Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups 65
Effect of SARS-CoV-2 vaccination on natural killer cell responses in multiple sclerosis 64
Disease Progression in Multiple Sclerosis: A Literature Review Exploring Patient Perspectives 57
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 53
Mesenchymal Stem/Stromal Cells for Multiple Sclerosis and Other Neurological Diseases 53
Cladribine Tablets Mode of Action, Learning from the Pandemic: A Narrative Review 52
Cyclophosphamide pulses therapy after natalizumab discontinuation in Multiple Sclerosis patients 52
To switch therapies in RRMS: why and when? A real-life multicentre study. 52
Ageing with MS: a cross sectional study 52
Totale 11.227
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.117
article - articoli 43.374
book - libri 0
conference - conferenze 428
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 315
Totale 88.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021509 0 0 0 0 0 54 69 74 55 110 75 72
2021/20221.094 45 28 84 111 44 94 40 252 74 113 66 143
2022/2023960 99 74 15 78 149 163 6 67 171 15 102 21
2023/2024765 41 84 9 88 66 84 53 70 69 18 46 137
2024/20252.508 104 214 96 158 294 293 262 421 121 138 183 224
2025/20261.887 510 114 244 388 538 93 0 0 0 0 0 0
Totale 12.051